Halozyme Therapeutics (HALO) Accumulated Expenses (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Accumulated Expenses data on file, last reported at $140.4 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $140.4 million, up 7.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $140.4 million (up 7.72% YoY), and the FY2025 annual result was $156.2 million, up 21.22% from the prior year.
• Accumulated Expenses fell to $140.4 million in Q1 2026 per HALO's latest filing, from $156.2 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $156.2 million in Q4 2025 and troughed at $19.1 million in Q1 2022.
• A 5-year average of $104.3 million and a median of $105.4 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses soared 336.34% in 2022, then retreated 1.98% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $99.8 million in 2022, then increased by 0.92% to $100.7 million in 2023, then increased by 27.98% to $128.9 million in 2024, then gained by 21.22% to $156.2 million in 2025, then dropped by 10.13% to $140.4 million in 2026.
• Business Quant data shows HALO's Accumulated Expenses at $140.4 million in Q1 2026, $156.2 million in Q4 2025, and $111.2 million in Q3 2025.